Strategic Partnerships ABL Bio is actively expanding its pipeline through global strategic partnerships, including recent collaborations with NovaBridge Biosciences and a licensing deal with GSK to leverage Grabody-B for neurodegenerative therapies, signaling strong BD potential for co-development and translational partnerships.

BBB Targeted Platform Grabody-B enhances blood-brain barrier penetration, positioning ABL Bio to address CNS and neurodegenerative indications with high unmet need, creating sales opportunities for CNS-focused pharma companies seeking efficient brain delivery platforms.

Bispecific Expertise ABL Bio’s Grabody-T and Grabody-I/Grabody-B bispecific antibody platforms offer modular, multi-disease engagement with oncology and neurodegeneration applications, enabling partnerships or licensing in both immuno-oncology and CNS spaces.

FinancialMomentum Recent financing of $55 million from Eli Lilly and ongoing collaborations indicate growing capital and validation from major sponsors, suggesting readiness for scaled joint development programs and upfront/milestone opportunities.

Mid-Sized Opportunity With a workforce under 200 and revenue in the tens of millions, ABL Bio presents as an attractive target for mid-sized collaborators seeking innovative bispecific programs without the footprint of larger biotechs, offering clear collaboration and licensing pathways.